423 related articles for article (PubMed ID: 8205641)
1. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
Mas Lago P; Ramon Bravo J; Andrus JK; Comellas MM; Galindo MA; de Quadros CA; Bell E
Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
[TBL] [Abstract][Full Text] [Related]
3. [A comparison of the effectiveness of mass immunization campaign of trivalent oral poliovirus vaccine (TOPV) by epidemiological serosurvey. Shandong Collaborating Group for Poliomyelitis Control and Surveillance, Jinan, Shandong].
Xu A
Zhonghua Liu Xing Bing Xue Za Zhi; 1992 Oct; 13(5):261-4. PubMed ID: 1338626
[TBL] [Abstract][Full Text] [Related]
4. Eradication of poliomyelitis in Cuba: a historical perspective.
Más Lago P
Bull World Health Organ; 1999; 77(8):681-7. PubMed ID: 10516790
[TBL] [Abstract][Full Text] [Related]
5. Early immunization of neonates with trivalent oral poliovirus vaccine.
Weckx LY; Schmidt BJ; Herrmann AA; Miyasaki CH; Novo NF
Bull World Health Organ; 1992; 70(1):85-91. PubMed ID: 1314711
[TBL] [Abstract][Full Text] [Related]
6. [Thermostability and immunogenicity of trivalent oral poliovirus vaccine produced by different countries].
Kong J
Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):151-4. PubMed ID: 8221837
[TBL] [Abstract][Full Text] [Related]
7. Two research projects seek to improve immunization practices.
Bull Pan Am Health Organ; 1992; 26(1):96-7. PubMed ID: 1318142
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana.
Osei-Kwasi M; Afari EA; Mimura K; Obeng-Ansah I; Ampofo WK; Nkrumah FK
Bull World Health Organ; 1995; 73(1):41-6. PubMed ID: 7704924
[TBL] [Abstract][Full Text] [Related]
9. Oral iodine supplementation does not reduce neutralizing antibody responses to oral poliovirus vaccine.
Taffs RE; Enterline JC; Rusmil K; Muhilal ; Suwardi SS; Rustama D; Djatnika ; Cobra C; Semba RD; Cohen N; Asher DM
Bull World Health Organ; 1999; 77(6):484-91. PubMed ID: 10427933
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt.
Linkins RW; Mansour E; Wassif O; Hassan MH; Patriarca PA
Bull World Health Organ; 1995; 73(5):589-95. PubMed ID: 8846484
[TBL] [Abstract][Full Text] [Related]
11. [Post-vaccination anti-poliomyelitis seroprevalence in an urban setting in Abidjan].
Akoua-Koffi G; Thonnon J; Kouassi-Renaud M; Dosso M; Ehouman A
Bull Soc Pathol Exot; 1995; 88(3):117-20. PubMed ID: 8555765
[TBL] [Abstract][Full Text] [Related]
12. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.
Stenvik M; Hovi L; Siimes MA; Roivainen M; Hovi T
Pediatr Infect Dis J; 1987 Dec; 6(12):1106-10. PubMed ID: 2829105
[TBL] [Abstract][Full Text] [Related]
13. Monovalent type 1 oral poliovirus vaccine in newborns.
el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
[TBL] [Abstract][Full Text] [Related]
15. Trial of a supplemental dose of four poliovirus vaccines.
Sutter RW; Suleiman AJ; Malankar P; Al-Khusaiby S; Mehta F; Clements GB; Pallansch MA; Robertson SE
N Engl J Med; 2000 Sep; 343(11):767-73. PubMed ID: 10984564
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine.
Krugman RD; Hardy GE; Sellers C; Parkman PD; Witte JJ; Meyer BC; Meyer HM
Pediatrics; 1977 Jul; 60(1):80-2. PubMed ID: 195265
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.
Waggie Z; Geldenhuys H; Sutter RW; Jacks M; Mulenga H; Mahomed H; De Kock M; Hanekom W; Pallansch MA; Kahn AL; Burton AH; Sreevatsava M; Hussey G
J Infect Dis; 2012 Jan; 205(2):228-36. PubMed ID: 22158680
[TBL] [Abstract][Full Text] [Related]
19. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.
John TJ; Jain H; Ravishankar K; Amaresh A; Verma H; Deshpande J; Pallansch MA; Singh AP; Sreevatsava M; Burton A; Malankar P; Chatterjee A; Sutter RW
Vaccine; 2011 Aug; 29(34):5793-801. PubMed ID: 21641951
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
